IL112895A - Pharmaceutical compositions for the treatment of obsessive-compulsive disorders comprising 5-HT2 antagonists - Google Patents
Pharmaceutical compositions for the treatment of obsessive-compulsive disorders comprising 5-HT2 antagonistsInfo
- Publication number
- IL112895A IL112895A IL11289595A IL11289595A IL112895A IL 112895 A IL112895 A IL 112895A IL 11289595 A IL11289595 A IL 11289595A IL 11289595 A IL11289595 A IL 11289595A IL 112895 A IL112895 A IL 112895A
- Authority
- IL
- Israel
- Prior art keywords
- obsessive
- antagonists
- treatment
- pharmaceutical compositions
- compulsive disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/209,084 US5618824A (en) | 1994-03-09 | 1994-03-09 | Treatment of obsessive-compulsive disorders with 5-HT2 antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
IL112895A0 IL112895A0 (en) | 1995-06-29 |
IL112895A true IL112895A (en) | 1999-12-31 |
Family
ID=22777257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11289595A IL112895A (en) | 1994-03-09 | 1995-03-06 | Pharmaceutical compositions for the treatment of obsessive-compulsive disorders comprising 5-HT2 antagonists |
Country Status (15)
Country | Link |
---|---|
US (1) | US5618824A (ko) |
EP (1) | EP0749309A1 (ko) |
JP (1) | JP3861250B2 (ko) |
KR (1) | KR100360132B1 (ko) |
CN (1) | CN1143321A (ko) |
AU (1) | AU690968B2 (ko) |
CA (1) | CA2183954C (ko) |
FI (1) | FI963511A0 (ko) |
HU (1) | HU218948B (ko) |
IL (1) | IL112895A (ko) |
NO (1) | NO963731L (ko) |
NZ (1) | NZ281768A (ko) |
TW (1) | TW301606B (ko) |
WO (1) | WO1995024194A1 (ko) |
ZA (1) | ZA951797B (ko) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6004980A (en) * | 1990-06-01 | 1999-12-21 | Merrell Pharmaceuticals, Inc. | (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
AU652759B2 (en) * | 1990-06-01 | 1994-09-08 | Aventisub Ii Inc. | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol |
EP0796619A1 (en) * | 1996-03-21 | 1997-09-24 | Merrell Pharmaceuticals Inc. | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders |
JPH11509827A (ja) | 1996-04-05 | 1999-08-31 | エフエムシー・コーポレイション | スピネルLi▲下1+x▼Mn▲下2―x▼0▲下4+y▼層間化合物の製造方法 |
US6028083A (en) * | 1997-07-25 | 2000-02-22 | Hoechst Marion Roussel, Inc. | Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
US6228864B1 (en) * | 1997-10-28 | 2001-05-08 | Vivus, Inc. | Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation |
US6713627B2 (en) * | 1998-03-13 | 2004-03-30 | Aventis Pharmaceuticals Inc. | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
TWI249526B (en) * | 1998-03-13 | 2006-02-21 | Aventis Pharma Inc | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
US20050261341A1 (en) * | 1998-03-13 | 2005-11-24 | Aventis Pharmaceuticals Inc. | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
SE9801516D0 (sv) * | 1998-04-30 | 1998-04-30 | Maria Carlsson | M100907/4-Piperidinemethanol derivatives for autism |
US6939879B2 (en) * | 1998-08-28 | 2005-09-06 | Aventis Pharmaceuticals Inc. | Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia |
US6277864B1 (en) | 1998-08-28 | 2001-08-21 | Aventis Pharmaceuticals Inc. | Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders |
NZ510083A (en) * | 1998-08-28 | 2003-08-29 | Aventis Pharma Inc | The use of R(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders |
JP2003505374A (ja) * | 1999-07-16 | 2003-02-12 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | 硫酸モノ−[3−({1−[2−(4−フルオロ−フェニル)−エチル]−ピペリジン−4−イル}−ヒドロキシ−メチル)−2−メトキシ−フェニル]エステル |
US6465490B1 (en) | 1999-07-16 | 2002-10-15 | Aventis Pharmaceuticals Inc. | Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester |
DE19934432A1 (de) | 1999-07-22 | 2001-02-01 | Merck Patent Gmbh | Indolderivate |
US20020099076A1 (en) * | 2000-05-25 | 2002-07-25 | Richard Scheyer D. | Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
DE102004010132A1 (de) * | 2004-02-27 | 2005-09-15 | Merck Patent Gmbh | Piperidinderivate |
AU2005309960A1 (en) * | 2004-11-22 | 2006-06-01 | Mallinckrodt Inc. | Process for the purification of benzphetamine hydrochloride |
FR2956031B1 (fr) * | 2010-02-11 | 2012-03-02 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc) |
WO2017214442A1 (en) | 2016-06-08 | 2017-12-14 | President And Fellows Of Harvard College | Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, rett syndrome, and fragile x syndrome |
WO2019232046A1 (en) | 2018-05-29 | 2019-12-05 | President And Fellows Of Harvard College | Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment |
WO2020198275A1 (en) | 2019-03-25 | 2020-10-01 | President And Fellows Of Harvard College | Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment |
WO2020237043A1 (en) * | 2019-05-22 | 2020-11-26 | President And Fellows Of Harvard College | Human tactile prepulse inhibition assay |
WO2021261471A1 (ja) * | 2020-06-23 | 2021-12-30 | 国立大学法人京都大学 | 強迫性障害の治療剤 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4783471A (en) * | 1985-07-02 | 1988-11-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine methanol derivatives and the uses thereof |
JPH02138214A (ja) * | 1987-12-10 | 1990-05-28 | Merrell Dow Pharmaceut Inc | 不安を治療する方法 |
ZA891901B (en) * | 1988-03-17 | 1989-11-29 | Merrell Dow Pharma | Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy |
EP0436245A1 (en) * | 1989-12-27 | 1991-07-10 | Duphar International Research B.V | Substituted 3,4-annelated benzimidazol-2(1H)-ones |
US5288749A (en) * | 1991-12-20 | 1994-02-22 | Abbott Laboratories | Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors |
US5441961A (en) * | 1992-08-27 | 1995-08-15 | Eli Lilly And Company | Substituted cyclo or bicycloalkylamides of (8β)-6-(substituted) ergolines |
US5264576A (en) * | 1992-10-22 | 1993-11-23 | Hoechst-Roussel Pharmaceuticals Incorporated | Pyrazolo[4,3-c]pyridines which are intermediates |
WO1994014801A1 (en) * | 1992-12-29 | 1994-07-07 | Smithkline Beecham Plc | Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists |
CA2166100A1 (en) * | 1993-06-23 | 1995-01-05 | Richard A. Glennon | Sigma receptor ligands and the use thereof |
GB9313913D0 (en) * | 1993-07-06 | 1993-08-18 | Smithkline Beecham Plc | Novel compounds |
-
1994
- 1994-03-09 US US08/209,084 patent/US5618824A/en not_active Expired - Lifetime
-
1995
- 1995-02-01 NZ NZ281768A patent/NZ281768A/en not_active IP Right Cessation
- 1995-02-01 CA CA002183954A patent/CA2183954C/en not_active Expired - Lifetime
- 1995-02-01 CN CN95192001A patent/CN1143321A/zh active Pending
- 1995-02-01 KR KR1019960704960A patent/KR100360132B1/ko not_active IP Right Cessation
- 1995-02-01 WO PCT/US1995/001306 patent/WO1995024194A1/en not_active Application Discontinuation
- 1995-02-01 HU HU9602449A patent/HU218948B/hu unknown
- 1995-02-01 EP EP95910903A patent/EP0749309A1/en not_active Withdrawn
- 1995-02-01 AU AU18694/95A patent/AU690968B2/en not_active Expired
- 1995-02-01 JP JP52345095A patent/JP3861250B2/ja not_active Expired - Lifetime
- 1995-03-03 ZA ZA951797A patent/ZA951797B/xx unknown
- 1995-03-06 IL IL11289595A patent/IL112895A/xx not_active IP Right Cessation
- 1995-03-06 TW TW084102122A patent/TW301606B/zh not_active IP Right Cessation
-
1996
- 1996-09-06 FI FI963511A patent/FI963511A0/fi not_active Application Discontinuation
- 1996-09-06 NO NO963731A patent/NO963731L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
FI963511A (fi) | 1996-09-06 |
KR100360132B1 (ko) | 2003-08-02 |
TW301606B (ko) | 1997-04-01 |
KR970701544A (ko) | 1997-04-12 |
NO963731L (no) | 1996-11-06 |
JPH09510441A (ja) | 1997-10-21 |
ZA951797B (en) | 1996-12-03 |
FI963511A0 (fi) | 1996-09-06 |
IL112895A0 (en) | 1995-06-29 |
EP0749309A1 (en) | 1996-12-27 |
NO963731D0 (no) | 1996-09-06 |
AU1869495A (en) | 1995-09-25 |
CA2183954C (en) | 2000-07-18 |
CA2183954A1 (en) | 1995-09-14 |
HU9602449D0 (en) | 1996-11-28 |
JP3861250B2 (ja) | 2006-12-20 |
AU690968B2 (en) | 1998-05-07 |
CN1143321A (zh) | 1997-02-19 |
US5618824A (en) | 1997-04-08 |
WO1995024194A1 (en) | 1995-09-14 |
HUT75317A (en) | 1997-05-28 |
HU218948B (hu) | 2001-01-29 |
NZ281768A (en) | 2001-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL112895A (en) | Pharmaceutical compositions for the treatment of obsessive-compulsive disorders comprising 5-HT2 antagonists | |
HUP9904525A3 (en) | Pharmaceutical compositions for the treatment of neurological disorders comprising s-(-)-n-propargyl-1-amino indan | |
HUP0103856A3 (en) | Pharmaceutical composition for the treatment of acute disorders | |
IL125735A0 (en) | Pharmaceutical compositions for the treatment of glaucoma | |
HUP0101627A3 (en) | Pharmaceutical compositions for treating neuropsychiatric disorders | |
NZ332780A (en) | Substituted amines for the treatment of neurological and neuropsychiatric disorders | |
HUP9701193A3 (en) | Use of n-(4-aryl-thiazol-2-yl)-sulfonamide derivatives for the preparation of pharmaceutical compositions treating neurological disorders, new derivatives, process for their preparation and pharmaceutical compositions containing them | |
IL117957A0 (en) | Pharmaceutical compositions for the treatment of impotence | |
HUP0301167A3 (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP9801995A3 (en) | Substituted pyrimidine-thioalkyl and alkylether compounds and their use for producing pharmaceutical compositions | |
GB2311940B (en) | Pharmaceutical compositions for the treatment of rhinitis | |
HUP9902405A3 (en) | Pharmaceutical compositions containing a serotonin antagonist for the treatment of the common cold or allergic rhinitis | |
HUP0200284A3 (en) | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders, process for their preparation and pharmaceutical compositions containing them | |
HUP0200287A3 (en) | Pharmaceutical compositions for the treatment of neurological or neuropsychiatric disorders | |
HUP0103832A3 (en) | Triazolopyridines for the treatment of thrombosis disorders, pharmaceutical compositions containing the same and process for preparation thereof | |
HUT77375A (hu) | Enterokinetikus hatású benzamidszármazékok, az ezeket tartalmazó gyógyszerkészítmények és eljárás a vegyületek előállítására | |
HK1112738A1 (en) | Arylsulfonamides and analogues as well as use for the treatment of neuro- degenerative disorders | |
IL119225A (en) | Pharmaceutical compositions for the treatment of asthma in mammals | |
HUP0200439A2 (en) | Isonipecotamides for the treatment of integrin-mediated disorders, process for their preparation and pharmaceutical compositions containing them | |
EP0981357A4 (en) | METHODS AND COMPOSITIONS APPLICABLE TO THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS | |
IL120005A0 (en) | Pharmaceutical compositions for the treatment of the eye | |
AU686084B3 (en) | Pharmaceutical compositions for the treatment of depressive disorders | |
HUP9902737A3 (en) | The use of aryl-cyclohexylamine derivatives for preparing pharmaceutical compositions suitable for treatment of cns disorders | |
IL130831A (en) | Imino-aza-anthrayclinone derivatives, process for their preparation and pharmaceutical compositions comprising them for the treatment of amyloidosis | |
IL116747A (en) | Use of 3,4-diphenyl chromans for the preparation of pharmaceutical compositions for the treatment of gynaecomastia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
HC | Change of name of proprietor(s) |
Owner name: AVENTIS INC. Free format text: FORMER NAME:MERRELL PHARMACEUTICALS INC. |
|
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |